Eli Lilly tops Q4 consensus, boosts FY23 EPS forecast
By Senad Karaahmetovic Shares of Eli Lilly (NYSE:LLY) are moving lower in pre-market despite the company reporting better-than-expected fourth-quarter results and raising its full-year EPS...
-
-
Eli Lilly earnings beat by $0.29, revenue fell short of estimates
Investing.com - Eli Lilly (NYSE: LLY) reported fourth quarter EPS of $2.09, $0.29 better than the analyst estimate of $1.80. Revenue for the quarter came in at $7.3B versus the consensus...
-
Lilly shares slip after FDA rejects early Alzheimer's drug approval
By Scott Kanowsky Investing.com -- Shares in Eli Lilly and Company (NYSE:LLY) dipped in early trading on Friday after the U.S. Food and Drug Administration decided not to give early...
-
Eli Lilly stock falls as increasing expenses weigh on profit forecast
By Senad Karaahmetovic Shares of Eli Lilly (NYSE:LLY) are down in pre-open Tuesday after the Indiana-based pharmaceutical giant offered a weaker-than-expected EPS forecast. Lilly offered...
-
Credit Suisse initiates coverage of large-cap pharma stocks - Merck started at outperform
By Sam Boughedda Credit Suisse analysts said Friday that the firm is initiating coverage of U.S. large-cap pharmaceuticals with four Outperform ratings, two Neutral ratings, and one...
-
Musk says Twitter’s blue check verification to relaunch in late-Nov
By Ambar Warrick Investing.com-- Elon Musk said on Wednesday that Twitter’s Blue Verified feature will relaunch on November 29, after the social media platform paused the subscription...
-
Roche shares fall after Alzheimer's drug trials fail to meet primary goals
By Scott Kanowsky Investing.com -- Roche Holding AG Participation (SIX:ROG) says two long-awaited late-stage studies showed that its Alzheimer's disease treatment failed to stem a slide in...
-
Controversial Blue service with verification to return next week: Musk
New Delhi, Nov 13 (IANS) After facing a barrage of fake profiles with verified badges, Elon Musk on Sunday said that the $8 Blue subscription service, pulled back by the company after facing...
-
Musk flip-flop continues, gray 'Official' badges back for some brands
New Delhi, Nov 11 (IANS) In an ongoing flip-flop on the future of Twitter, Elon Musk has again brought back gray 'Official' verification badge for some accounts in select parts of the world...
-
Eli Lilly Drops After Cutting Guidance, BMO Says Buy the Dip
By Senad Karaahmetovic Shares of Eli Lilly (NYSE:LLY) are trading more than 3% lower in pre-market Tuesday after the biopharma giant slashed its full-year guidance to reflect FX...
-
Eli Lilly & Co. Tops Q3 EPS by 7c; Offers FY22 EPS Guidance
Eli Lilly & Co. (LLY) reported Q3 EPS of $1.98, $0.07 better than the analyst estimate of $1.91. Revenue for the quarter came in at $6.94 billion versus the consensus estimate of $6.91...
-
Eli Lilly earnings, Revenue beat in Q3
Investing.com - Eli Lilly (NYSE:LLY) reported on Tuesday third quarter {{erl-273||earnings that beat analysts' forecasts and revenue that topped expectations. Eli Lilly announced earnings...
-
Top 5 Things to Watch in Markets in the Week Ahead
By Noreen Burke Investing.com -- The Federal Reserve and the Bank of England are all but certain to deliver jumbo 75-basis-point rate hikes on Wednesday and Thursday, respectively, as the...
-
Goldman Sachs, Johnson & Johnson, Apple Rise Premarket; Hasbro Falls
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Tuesday, October 18th. Please refresh for updates. Goldman Sachs (NYSE:GS) stock rose 2.8% after the investment...
-
Analysts Discuss Implications for Eli Lilly After Biogen's Big Win
By Senad Karaahmetovic Shares of Eli Lilly (NYSE:LLY) are up almost 8% in sympathy with Biogen (NASDAQ:BIIB), which trades about 54% higher in pre-open Wednesday. Biogen announced that its...
-
Eli Lilly & Co. the 'Most Attractive Name' in UBS Large Cap Coverage
By Sam Boughedda A UBS analyst raised Eli Lilly's (NYSE:LLY) rating to Buy from Neutral, with its price target raised to $363 per share from $335. The analyst explained, in a research note,...
-
It's Good to be Eli Lilly in 2022 Says Citi Analyst
By Sam Boughedda Eli Lilly & Co.'s (NYSE:LLY) price target was raised to $370 from $285, with its Buy rating maintained at Citi on Thursday. An analyst stated in his research note that "it's...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
